Skip to content

News Releases

Filter Releases
 
News Releases
Date Title and Summary View
Mar 17, 2017
-- Transaction to result in Nasdaq-listed company focused on developing novel treatments for cancer -- -- Molecular Templates lead drug candidate being developed to treat non-Hodgkin's Lymphoma (NHL); engineered toxin body (ETB) platform has applications in multiple oncology indications -- -- Combined company will be capitalized to support ad...
Dec 19, 2016
-- Preclinical studies will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia cancer cell lines with high AKR1C3 expression -- SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer,...
Nov 15, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will be presenting at the Stifel Healthcare Conference on November 16, 2016, ...
Nov 7, 2016
-- Planning to initiate a clinical trial of evofosfamide in combination with checkpoint inhibitors -- SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the third qu...
Oct 25, 2016
IRVING, Texas and SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 /PRNewswire/ -- Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products for...
Sep 29, 2016
-- Tarloxotinib Primary Interim Response Rate Endpoint Achieved in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Skin (SCCS) but not Achieved in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) or Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC); Company to Discontinue Inves...
Aug 1, 2016
-- Presented additional subset data at ASCO from Phase 3 MAESTRO trial of evofosfamide in pancreatic cancer; meaningful improvement in overall survival in patients from Asia -- SOUTH SAN FRANCISCO, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing ...
Jun 6, 2016
CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced multiple presentations on clinical trials on its hypoxia-activated prodrugs, evofosfamide and tarloxotinib at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 through 7, 2016 in Chicago, Ill. Today, Thresh...
Jun 1, 2016
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on June 7, 2016 at 3:30 p.m. Eastern Time. ...
May 5, 2016
SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the first quarter ended March 31, 2016 and provided an update on the Company's corporate and clinical development activi...
Mar 21, 2016
SOUTH SAN FRANCISCO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, announced the appointment of Stewart M. Kroll as Chief Operating Officer. Mr. Kroll will serve as the Company's principal operating officer, will continue ...
Mar 10, 2016
-- Rights to Evofosfamide and Relevant Merck KGaA, Darmstadt, Germany Technology Returned to Threshold; Merck KGaA, Darmstadt, Germany Retains Certain Royalty and Milestone Payments Dependent Upon Successful Development and Commercialization of Evofosfamide -- -- Additional Analyses of Data from the MAESTRO Study in Pancreatic Cancer Demonstra...
Mar 1, 2016
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016, at 9:20 a.m. Eastern Time. A live webcast of...
Jan 11, 2016
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/11/16 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold. The companies have a global license...
Dec 18, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* ("tarloxotinib"...
Page:
...
Next Last